TCOM shares fell approximately 12.4% over the past 30 days, closing at $41.38 on July 8, 2026, down from $47.21 on June 8. The sharpest single-day decline occurred on June 25 after the company reported Q1 2026 earnings and issued significantly weaker Q2 revenue guidance of just 3%–8% year-over-year growth.

Progressive Corporation is set to release its June 2026 results on July 15, 2026, continuing its practice of monthly reporting on premiums, policies, and combined ratios. Analysts project second-quarter 2026 EPS around $4.59, following a Q1 2026 beat where actual EPS reached $4.96 versus estimates of $4.82.

PepsiCo is set to report second-quarter 2026 results on July 9 before the market opens. Analysts project earnings per share of approximately $2.19 to $2.21.

Total sales reached a record $448.5 million, up 6.3% year over year. Metal Coatings sales rose 12.3% to $210.3 million on higher volumes.

PriceSmart reported total revenue of $1.48 billion for the fiscal third quarter of 2026, exceeding consensus estimates of approximately $1.43 billion to $1.45 billion. Diluted earnings per share came in at $1.28, compared to analyst expectations ranging from $1.19 to $1.32.

Net revenues reached $1.562 billion, rising 8% year-over-year on a reported basis and 6% on an organic basis. Adjusted diluted earnings per share climbed 27% to $0.28, exceeding analyst expectations.

Bloom Energy shares fell -8.66% during regular trading on Tuesday, dropping to $246.23 after closing at $269.57 the prior session. The decline was driven by broad-based profit-taking following a massive rally fueled by the recent $25 billion Brookfield AI infrastructure financing deal.

ABTC shares fell -7.60% during Tuesday's regular session, sliding from a prior close of $6.52 to an intraday low near $6.02, compounding the previous session's -23.09% collapse. The selloff extends the post-reverse-split rout after the company's 1-for-15 reverse stock split began trading on a split-adjusted basis on July 6, implemented to maintain Nasdaq's minimum bid price compliance.

OUST fell -5.74% during regular trading on July 8, extending a multi-day selloff that began after the company priced a $200M dilutive stock offering at $55.22 per share on July 2. The stock has now dropped approximately -31% from its July 1 close of $60.02, breaking well below the offering price as investors continue to digest the ~5.6% share dilution completed on July 6.

MRNA fell -7.02% during regular market hours on Tuesday, retreating to $74.17 from a prior close of $79.77, as the stock gave back a portion of its recent explosive rally. The decline represents profit-taking after shares surged more than +70% over the past month and hit a 52-week high of $85.60 on July 6, driven by a unanimous 9-0 FDA advisory panel vote backing the company's mRNA flu vaccine.

HP Inc. shares declined approximately 10.3% over the past 30 days, falling from $25.58 to $22.96, as post-earnings optimism faded and memory-cost headwinds returned to the forefront.

NVTS fell -9.11% during regular trading on July 8, dropping to $12.72 after closing at $13.99 the previous session. The primary catalyst is a patent infringement lawsuit filed by rival Wolfspeed after Tuesday's close, alleging NVTS's GaNFast and GeneSiC product lines infringe multiple Wolfspeed patents.

IQMX fell -9.62% during regular trading on Tuesday, sliding to $11.65 from a prior close of $12.89, extending a two-day selloff after last week's post-SPAC debut surge. The decline occurred despite IQM announcing a major contract win with the LUMI AI Factory to deploy its Halocene H4 quantum computer, a deal whose value was already disclosed in the July 1 prospectus and largely priced in.

IPX fell -8.16% during regular trading on July 8, sliding from a prior close of $25.85 to $23.74, extending losses after an -8.85% drop the previous session. The selloff was triggered by the pricing of a $50 million underwritten public offering of 2.275 million ADSs at $21.98 per ADS — a steep discount to the prevailing market price.

MXL shares are down -6.94% during regular trading on Tuesday, falling to $79.86 from a previous close of $85.82, extending a brutal multi-session selloff. The decline continues fallout from MaxLinear's late-June removal from multiple Russell value benchmarks, including the Russell 3000, 2000, and Small Cap Composite Value indexes, forcing index-tracking funds to rebalance and exit positions.

FCEL shares fell -13.02% to $22.58 from Tuesday's $25.96 close, with the vast majority of the decline occurring in after-hours and premarket trading before Wednesday's regular session open. The selloff was triggered by the company's announcement of a dilutive public stock offering, initially launched at $200 million after Tuesday's close.

Tango Therapeutics shares surged approximately 49% over the past 30 days, driven by groundbreaking Phase 1/2 clinical trial results for its lead PRMT5 inhibitor, vopimetostat. The vopimetostat plus daraxonrasib combination achieved a 92% objective response rate in heavily pre-treated MTAP-deleted pancreatic cancer patients, with a 90% six-month progression-free survival rate.

Amneal Pharmaceuticals (AMRX) surged approximately 24% over the last 30 days, climbing from $13.71 on June 8 to $17.05 by July 7, 2026. The rally was fueled by a series of positive catalysts, including FDA approval of romidepsin injection solution, selection for the FDA PreCheck Pilot Program, and inclusion in multiple Russell 2000 Defensive indexes.

ORKA shares surged approximately 31.9% over the last 30 days, climbing from $64.06 on June 8 to $84.50 on July 7, 2026. The rally was fueled by a major collaboration with Halozyme to develop ORKA-001 using Hypercon™ technology, a $700 million follow-on offering that strengthened the balance sheet, and a series of analyst upgrades and price target increases.

DigitalOcean Holdings (DOCN) shares declined approximately 19% over the last 30 days, retreating from a 52-week high of $180.50 reached in early June 2026 to $137.04 as of July 7, 2026. The pullback largely reflects profit-taking after a meteoric year-to-date rally of roughly 200%, rather than any deterioration in the company's fundamental business performance.